Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new genomic classification tool is helping doctors figure out which prostate cancer patients need aggressive treatment — and who might benefit from de-escalation. The STRATOS-P model, tested on nearly 2,500 veterans, found men with favorable genetic profiles lived a median of 87 months vs. just 31 months for those with unfavorable profiles. Experts say routine tumor biopsies at metastasis could soon become standard of care.
A genomic classification tool called STRATOS-P is showing real promise in predicting survival outcomes for men with metastatic prostate cancer — and could soon guide decisions about who needs aggressive therapy versus who might safely scale back. The model, trained on nearly 2,500 veterans with metastatic hormone-sensitive prostate cancer, uses 16 cancer-associated gene mutations to sort patients into favorable, intermediate, and unfavorable risk groups.
The survival differences are striking: men with favorable profiles had a median overall survival of 87 months, compared to 52 months for intermediate and just 31 months for unfavorable classifications. The findings held up in a separate non-veteran validation cohort, lending credibility to the tool's broader applicability. Researchers say the next step is a clinical trial testing whether men with favorable genomic profiles can safely de-escalate androgen deprivation therapy — a treatment known for significant side effects including cardiovascular risk.
By the Numbers:
Why it matters: This tool could personalize prostate cancer care at scale — helping spare low-risk patients from grueling treatments while ensuring high-risk patients get what they need. With whole-genome sequencing now available for as little as $300 in research settings, experts say broad access may be within reach.
